Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of GFH018 in Advanced Solid Tumors
NCT05051241Phase 1Completed
- Sponsor
- GenFleet Therapeutics
- Start
- Aug 2019
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gfh018 in solid tumor (10 cohorts), sponsored by GenFleet Therapeutics. Primary endpoint: Incidence of Dose-limiting Toxicity at 31 days. Started Aug 2019; status: completed.
02
Drugs
gfh018
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05051241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05051241.